- Mind Cure Health Inc. announced Jerry White’s appointment into the company’s advisory board
- Mr. White brings a wealth of experience from his years of powering global movements and working with key leaders and personalities around the world
- MINDCURE forecasts that with Mr. White’s addition to the board, the company will be well-positioned to achieve bigger and better goals, all while working towards its overall vision of building mental wealth globally
Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) announced that it has appointed Jerry White as an advisor to the company. Mr. White would be an excellent addition to the company’s advisory board given his expertise, ambition, and track record of the achievements (https://ibn.fm/Fnt3f).
In an official statement confirming the appointment, Mr. White reckoned:
“I’m thrilled today to be joining MINDCURE as an advisor. The company’s ambition to improve access to mental health through new technologies and psychedelic medicines is timely and vital.”
Mr. White has been recognized globally for his efforts in engaging large audiences to power global movements. is a recognized leader of the International Campaign to Ban Landmines and a co-recipient of the 1997 Nobel Peace Prize. He is also known for leading high-impact campaigns, some of which have led to international treaties (https://ibn.fm/kYy7j). Mr. White worked closely with the late Princess Diana, the Princess of Wales, and President Obama, serving as the United States (“US”) Deputy Assistant Secretary of State.
Kelsey Ramsden, the President and Chief Executive Officer (“CEO”) of Mind Cure, acknowledged that Mr. White would be a valuable asset to the company’s advisory board.
“Never shying away from audacious goals, driving transformational global movements, asking the toughest of questions, and translating them to strategy- this is what Jerry brings and why I am so thrilled to welcome him to the advisory board at MINDCURE. It’s an honor to welcome a truly noble and humane impact strategist to our advisory board,” Mr. Ramsden noted. “I look forward to working with Jerry on our visionary strategy to build mental wealth worldwide,” he added (https://ibn.fm/ro9X3).
MINDCURE is a life sciences enterprise that develops digital therapeutics technology. It is also known for researching psychedelic compounds to scale science-based and evidence-backed mental health therapy globally rapidly. With 40% of adults in the United States dealing with mental health issues or substance abuse, psychedelics offer healthier and more promising alternatives for healing (https://ibn.fm/Jftpj). MINDCURE is well-positioned to address this growing problem.
With Jerry White’s addition to the advisory board, MINDCURE hopes to achieve bigger and better goals while working towards its overall vision of building mental wealth globally.
For more information, visit the company’s website at www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
